El efecto de la melatonina sobre el metabolismo y el ciclo sueño-vigilia
Palabras clave:
Melatonina, diabetes, insomnio, cardiovascular, Endocrinología
Resumen
El objetivo de este estudio fue investigar la influencia de la melatonina en el metabolismo y la implementación del ciclo sueño-vigilia. Metodología. Las publicaciones para esta revisión se obtuvieron de las bases de datos PubMed, MedLine y Google Scholar. Resultados. La melatonina es la principal hormona que comunica el reloj circadiano principal, ubicado en el núcleo supraquiasmático del hipotálamo, y el reloj biológico periférico ubicado en las células cerebrales y otros órganos. La producción de melatonina está relacionada con los ciclos de día y noche, y la producción máxima de la hormona se produce durante la noche. Teniendo en cuenta los mecanismos fisiopatológicos desencadenados por la deficiencia de melatonina, surge razonablemente la pregunta sobre las posibilidades de tratar los trastornos metabólicos (incluida la diabetes tipo 2), la patología cardiovascular y los trastornos del sueño con preparados de melatonina. Las publicaciones nacionales y extranjeras informan sobre el uso clínicamente exitoso de dichos medicamentos para mejorar la calidad del sueño, aumentar la sensibilidad a la glucosa, reducir la presión arterial, reducir la isquemia miocárdica y mejorar los parámetros antropométricos. Todo esto hace de la melatonina un fármaco prometedor para controlar los riesgos cardiovasculares en el contexto de trastornos metabólicos.
Descargas
La descarga de datos todavía no está disponible.
Citas
Balmik AA, Chinnathambi S. (2018). Multi-Faceted Role of Melatonin in Neuroprotection and Amelioration of Tau Aggregates in Alzheimer's Disease. J Alzheimers Dis., 62:1481–93. doi: 10.3233/JAD-170900.
Bazyar H, ZareJavid A, BaviBehbahani H, Moradi F, MoradiPoode B, Amiri P. (2021). Consumption of melatonin supplement improves cardiovascular disease risk factors and anthropometric indices in type 2 diabetes mellitus patients: a double-blind, randomized, placebo-controlled trial.Trials, 22(1):231. doi: 10.1186/s13063-021-05174-z.
Berger AA, Sottosanti ER, Winnick A, Keefe J, Gilbert E, Hasoon J, Thase ME, Kaye AD, Viswanath O, Urits I. (2022). Suvorexant in the Treatment of Difficulty Falling and Asleep (Insomnia). Psychopharmacol Bull., 52(1):68-90.
BonhamMP, Kaias E, ZimbergI, Leung G, Davis R, Sletten TL, Windsor-Aurbrey H, Huggins CE. (2021).Effect of night time eating on postprandial triglyceride metabolism in healthy adults: a systematic literature review. Journal of Biological Rhytms, 34. https://doi.org/10.1177/0748730418824214.
Borghi C, Cicero AF. (2017). Nutraceuticals with clinically detectable blood pressure lowering effect: a review of available randomized clinical trials and their meta-analyses. Br J ClinPharmacol., 83:163–171. doi: 10.1111/bcp.12902.
Bueno APR, Savi FM, Alves IA, Bandeira VAC. (2021). Regulatory aspects and evidences of melatonin use for sleep disorders and insomnia: an integrative review. ArqNeuropsiquiatr., 79(8):732-742. doi: 10.1590/0004-282X-ANP-2020-0379.
Buonfiglio D, Parthimos R, Dantas R, Cerqueira Silva R, Gomes G, Andrade-Silva J, Ramos- Lobo A, Amaral FG, Matos R, Sinesio J, Motta-Teixeira LC, Donato J, Reiter RJ, Cipolla- Neto J. (2018). Melatonin Absence Leads to Long-Term Leptin Resistance and Overweight in Rats. Front Endocrinol (Lausanne).,9:122. doi: 10.3389/fendo.2018.00122.
Buonfiglio D, Tchio C, Furigo I, Donato J Jr, Baba K, Cipolla-Neto J, Tosini G. (2019). Removing melatonin receptor type 1 signaling leads to selective leptin resistance in the arcuate nucleus. J Pineal Res., 67:e12580. doi: 10.1111/jpi.12580.
Canpolat S, Aydin M, Yasar A, Colakoglu N, Yilmaz B, Kelestimur H. (2006). Effects of pinealectomy and exogenous melatonin on immunohistochemical ghrelin staining of arcuate nucleus and serum ghrelin leves in the rat. NeurosciLett., 410:132–6. doi: 10.1016/j.neulet.2006.09.071.
Challet E. (2015). Keeping circadian time with hormones. Diabetes ObesMetab., 17(Suppl 1):76–83. doi: 10.1111/dom.12516.
Chawla S, Beretoulis S, Deere A, Radenkovic D. (2021). The Window Matter: A Systematic of Time Restricted Eating Strategies in Relation to Cortisol and Melatonin Secretion. Nutrients, 13(8):2525. doi: 10.3390/nu13082525.
Das R, Balmik AA, Chinnathambi S. (2020). Melatonin Reduces GSK3beta-Mediated Tau Phosphorylation, Enhances Nrf2 Nuclear Translocation and Anti-Inflammation. ASN Neuro., 12: 1759091420981204. doi: 10.1177/1759091420981204.
Czvetkova ES, Romanczova TI, Polue`ktov MG, Runova GE, Glinkina IV, Fadeev VV. (2021).The importance of melatonin in the regulation of metabolism, eating behavior, sleep and the prospects for its use in exogenous constitutional obesity.Obesity and metabolism, 18(2):112-124. doi: https://doi.org/10.14341/omet12279. (In Russian).
De Crescenzo F, D'Alò GL, Ostinelli EG, Ciabattini M, Di Franco V, Watanabe N, Kurtulmus A, Tomlinson A, Mitrova Z, Foti F, Del Giovane C, Quested DJ, Cowen PJ, Barbui C, Amato L, Efthimiou O, Cipriani A. (2022). Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic and network meta-analysis. Lancet, 400(10347):170-184. doi: 10.1016/S0140-6736(22)00878-9.
Dehdashtian E, Mehrzadi S, Yousefi B, HosseinzadehA, ReiterRJ, SafaM, GhaznaviH, NaseripourM. (2018). Diabetic rethinopathy pathogenesis and the ameliorating effects of melatonin; involvement of autophagy, inflammation and oxidative stress. Life Sci., 193:20–33. doi: 10.1016/j.lfs.2017.12.001.
Ding M, Feng N, Tang D, TangD, FengJ, LiZ, JiaM, LiuZ, GuX, WangY, FuF, PeiJ. (2018). Melatonin prevents Drp1-mediated mitochondrial fission in diabetic hearts through SIRT1- PGC1α pathway. J Pineal Res., 65(2):e12491. doi: 10.1111/jpi.12491.
Dominguez-Rodriguez A, Abreu-Gonzalez P, de la Torre-Hernandez JM, Consuegra- SanchezL, PiccoloR, Gonzalez-GonzalezJ, Garcia-CamareroT, Del Mar Garcia- SaizM, Aldea-PeronaA, ReiterRJ. (2017). Usefulness of early treatment with melatonin to reduce infarct size in patients with ST-elevation Myocardial infarction receiving percutaneous coronary intervention. Am J Cardiol., 120:522–526. doi: 10.1016/j.amjcard.2017.05.018.
Halpern B, Mancini MC, Bueno C, BarcelosIP, de MeloME, LimaMS, CarneiroCG, SapienzaMT, BuchpiguelCA, do AmaralFG, Cipolla-NetoJ. (2019). Melatonin increases brown adipose tissue volume and activity in patients with melatonin deficiency: a proof-of-concept study. Diabetes, 68:947–952. doi: 10.2337/db18-0956.
Jockers R, Delagrange P, Dubocovich ML, Markus RP, Renault N, Tosini G., Cecon E, ZlotosDP. (2016). Update on melatonin receptors: IUPHAR Review 20. Br J Pharmacol.,173:2702–25. doi: 10.1111/bph.13536.
Kandimalla R, Thirumala V, Reddy PH. (2017). Is Alzheimer's disease a Type 3 Diabetes? A critical appraisal. BiochimBiophysActaMol Basis Dis., 1863:1078– 89. doi: 10.1016/j.bbadis.2016.08.018.
Karamitri A, Renault N, Clement N, Guillaume JL, Jockers R. (2013). Minireview: Toward the Establishment of a Link between Melatonin and Glucose Homeostasis: Association of Melatonin MT2 Receptor Variants with Type 2 Diabetes. MolEndocrinol.,27:1217– 1233. doi: 10.1210/me.2013-1101.
Lin YC, Hsieh IC, Chen PC. (2015). Utilizing the metabolic syndrome component count in workers' health surveillance: An example of day-time vs. day-night rotating shift workers. Int J Occup Med Environ Health.,28:675–88. doi: 10.13075/ijomeh.1896.00335.
Logan RW, McClungCA. (2019). Rhythms of life: circadian disruption and brain disorders across the lifespan. Nature Reviews Neuroscience, 20(1):49–65. doi: 10.1038/s41583-018-0088-y.
Maras A, Schroder CM, Malow BA, Findling RL, Breddy J, Nir T, Shahmoon S, Zisapel N, Gringras P. (2018). Long-Term Efficacy and Safety of Pediatric Prolonged-Release Melatonin in Children with Autism Spectrum Disorder. J Child Adolesc Psychopharmacol., 28(10):699-710. doi: 10.1089/cap.2018.0020.
Molzof HE, Wirth MD, Burch JB, Shivappa N, Hebert JR, Johnson RL,Gamble KL. (2017).The impact of meal timing on cardiometabolic syndrome indicators in shift workers. Chronobiol Int., 34:337–48. doi: 10.1080/07420528.2016.
Morris CJ, YangJN, GarciaJI, MyersS, BozziI, WangW, BuxtonOM, SheaSA, Scheer FAJ. (2015). Endogenous circadian system and circadian misalignment impact glucose tolerance via separate mechanisms in humans. Proc. Natl Acad. Sci. USA., 112:E2225–E2234.doi: 10.1073/pnas.1418955112.
Nedogoda SV, Smirnova VO, Bary`kina IN, Salasyuk AS, XripaevaVYu, Palashkin RV, Popova EA. (2017).Effect of melatonin therapy on endothelial function, blood pressure and vascular stiffness in patients with metabolic syndrome and sleep disorders.Arterial hypertension, 23(2):150–159. doi:10.18705/1607-419X-2017-23-2-150-159. (In Russian).
Ozkalayci F, Kocabas U, Altun BU, Pandi-Perumal S, Altun A. (2021). Relationship Between Melatonin and Cardiovascular Disease. Cureus, 13(1):e12935. doi: 10.7759/cureus.12935.
Queiroz JDN, Macedo RCO, Tinsley GM, Reischak-Oliveira A. (2021). Time-restricted eating and circadian rhythms: The biological clock is ticking. Crit. Rev. Food Sci. Nutr., 61(17):2863–3875. doi: 10.1080/10408398.2020.1789550.
Pizova NV, Pizov AV, Solov`eva IN. (2022). Insomnia: risk factors, gender and age characteristics and approaches to treatment.Medical advice, 16(11):62-70. https://doi.org/10.21518/2079-701X-2022-16-11-62-70. (In Russian).
Popov SS,Pashkov AN, Shul`gin KK. (2015). The effect of combination therapy with melaxen on carbohydrate and lipid metabolism in patients with type 2 diabetes mellitus complicated by non-alcoholic steatohepatitis.Bulletin of Voronezh State University, 4:66-70. (In Russian).
Ramos AR,Weng J, WallaceDM, PetrovMR, WohlgemuthWK, Sotres-Alvarez D, Loredo JS, Reid KJ, ZeePC, Mossavar-RahmaniY, PateSR. (2018). Sleep patterns and hypertension using actigraphy in the Hispanic Community Health Study/Study of Latinos.Chest.,153:87– 93. doi: 10.1016/j.chest.2017.09.028.
Shen S, Liao Q, Wong YK, Chen X, Yang C, Xu C, Sun J, Wang J. (2022). The role of melatonin in the treatment of type 2 diabetes mellitus and Alzheimer’s disease. Int J Biol Sci., 18(3):983-994. doi: 10.7150/ijbs.66871.
Sobko DI, Ilashchuk TO, Navchuk IV. (2021). Melatonin and Grhelin as “Early” Prognosis Markers of Progression of Arterial Hypertension and Osteoarthritis in the Case of Their Comorbidity. WiadLek., 74(3 cz 2):697-701.
Stenvers DJ, ScheerFAJ, SchrauwenP, la FleurSE, KalsbeekA. (2019). Circadian clocks and insulin resistance. Nature Reviews Endocrinology, 15(2):75–89. doi: 10.1038/s41574-018-0122-1.
Sumsuzzman DM, Choi J, Jin Y, Hong Y. (2021). Neurocognitive effects of melatonin treatment in healthy adults and individuals with Alzheimer’s disease and insomnia: A systematic review and meta-analysis of randomized controlled trials. NeurosciBiobehav Rev., 127:459-473. doi: 10.1016/j.neubiorev.2021.04.034.0
Tobaldini E, Fiorelli EM, Solbiati M, Costantino G, Nobili L, Montano N. (2019). Short sleep duration and cardiometabolic risk: from pathophysiology to clinical evidence. Nat Rev Cardiol., 16:213–224. https://doi. org/10.1038/s41569-018-0109-6.
Vasendin DV, Michurina SV, IshhenkoIYu. (2023). The effect of melatonin on the ultrastructural organization of the liver in obesity and type 2 diabetes mellitus.Cardiovascular Therapy and Prevention,22(6S):110. (In Russian).
Vasendin DV, Michurina SV, IshhenkoIYu. (2023). The influence of a melatonin-containing composition on the state of lipid metabolism in the liver in obesity and type 2 diabetes mellitus.Cardiovascular Therapy and Prevention, 22(6S):110. (In Russian).
Wajid F, Poolacherla R, Mim FK, Bangash A, Rutkofsky IH. (2020). Therapeutic potential of melatonin as a chronobiotic and cytoprotective agent in diabetes mellitus. J Diabetes Metab Disord., 19(2):1797-1825. doi: 10.1007/s40200-020-00585-2.
Zhu H, Zhao ZJ, Liu HY, Cai J, Lu QK, Ji LD, Xu J. (2023). The melatonin receptor 1 B gene links circadian rhythms and type 2 diabetes mellitus: an evolutionary story. Ann Med., 55(1):1262-1286. doi: 10.1080/07853890.2023.2191218.
Bazyar H, ZareJavid A, BaviBehbahani H, Moradi F, MoradiPoode B, Amiri P. (2021). Consumption of melatonin supplement improves cardiovascular disease risk factors and anthropometric indices in type 2 diabetes mellitus patients: a double-blind, randomized, placebo-controlled trial.Trials, 22(1):231. doi: 10.1186/s13063-021-05174-z.
Berger AA, Sottosanti ER, Winnick A, Keefe J, Gilbert E, Hasoon J, Thase ME, Kaye AD, Viswanath O, Urits I. (2022). Suvorexant in the Treatment of Difficulty Falling and Asleep (Insomnia). Psychopharmacol Bull., 52(1):68-90.
BonhamMP, Kaias E, ZimbergI, Leung G, Davis R, Sletten TL, Windsor-Aurbrey H, Huggins CE. (2021).Effect of night time eating on postprandial triglyceride metabolism in healthy adults: a systematic literature review. Journal of Biological Rhytms, 34. https://doi.org/10.1177/0748730418824214.
Borghi C, Cicero AF. (2017). Nutraceuticals with clinically detectable blood pressure lowering effect: a review of available randomized clinical trials and their meta-analyses. Br J ClinPharmacol., 83:163–171. doi: 10.1111/bcp.12902.
Bueno APR, Savi FM, Alves IA, Bandeira VAC. (2021). Regulatory aspects and evidences of melatonin use for sleep disorders and insomnia: an integrative review. ArqNeuropsiquiatr., 79(8):732-742. doi: 10.1590/0004-282X-ANP-2020-0379.
Buonfiglio D, Parthimos R, Dantas R, Cerqueira Silva R, Gomes G, Andrade-Silva J, Ramos- Lobo A, Amaral FG, Matos R, Sinesio J, Motta-Teixeira LC, Donato J, Reiter RJ, Cipolla- Neto J. (2018). Melatonin Absence Leads to Long-Term Leptin Resistance and Overweight in Rats. Front Endocrinol (Lausanne).,9:122. doi: 10.3389/fendo.2018.00122.
Buonfiglio D, Tchio C, Furigo I, Donato J Jr, Baba K, Cipolla-Neto J, Tosini G. (2019). Removing melatonin receptor type 1 signaling leads to selective leptin resistance in the arcuate nucleus. J Pineal Res., 67:e12580. doi: 10.1111/jpi.12580.
Canpolat S, Aydin M, Yasar A, Colakoglu N, Yilmaz B, Kelestimur H. (2006). Effects of pinealectomy and exogenous melatonin on immunohistochemical ghrelin staining of arcuate nucleus and serum ghrelin leves in the rat. NeurosciLett., 410:132–6. doi: 10.1016/j.neulet.2006.09.071.
Challet E. (2015). Keeping circadian time with hormones. Diabetes ObesMetab., 17(Suppl 1):76–83. doi: 10.1111/dom.12516.
Chawla S, Beretoulis S, Deere A, Radenkovic D. (2021). The Window Matter: A Systematic of Time Restricted Eating Strategies in Relation to Cortisol and Melatonin Secretion. Nutrients, 13(8):2525. doi: 10.3390/nu13082525.
Das R, Balmik AA, Chinnathambi S. (2020). Melatonin Reduces GSK3beta-Mediated Tau Phosphorylation, Enhances Nrf2 Nuclear Translocation and Anti-Inflammation. ASN Neuro., 12: 1759091420981204. doi: 10.1177/1759091420981204.
Czvetkova ES, Romanczova TI, Polue`ktov MG, Runova GE, Glinkina IV, Fadeev VV. (2021).The importance of melatonin in the regulation of metabolism, eating behavior, sleep and the prospects for its use in exogenous constitutional obesity.Obesity and metabolism, 18(2):112-124. doi: https://doi.org/10.14341/omet12279. (In Russian).
De Crescenzo F, D'Alò GL, Ostinelli EG, Ciabattini M, Di Franco V, Watanabe N, Kurtulmus A, Tomlinson A, Mitrova Z, Foti F, Del Giovane C, Quested DJ, Cowen PJ, Barbui C, Amato L, Efthimiou O, Cipriani A. (2022). Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic and network meta-analysis. Lancet, 400(10347):170-184. doi: 10.1016/S0140-6736(22)00878-9.
Dehdashtian E, Mehrzadi S, Yousefi B, HosseinzadehA, ReiterRJ, SafaM, GhaznaviH, NaseripourM. (2018). Diabetic rethinopathy pathogenesis and the ameliorating effects of melatonin; involvement of autophagy, inflammation and oxidative stress. Life Sci., 193:20–33. doi: 10.1016/j.lfs.2017.12.001.
Ding M, Feng N, Tang D, TangD, FengJ, LiZ, JiaM, LiuZ, GuX, WangY, FuF, PeiJ. (2018). Melatonin prevents Drp1-mediated mitochondrial fission in diabetic hearts through SIRT1- PGC1α pathway. J Pineal Res., 65(2):e12491. doi: 10.1111/jpi.12491.
Dominguez-Rodriguez A, Abreu-Gonzalez P, de la Torre-Hernandez JM, Consuegra- SanchezL, PiccoloR, Gonzalez-GonzalezJ, Garcia-CamareroT, Del Mar Garcia- SaizM, Aldea-PeronaA, ReiterRJ. (2017). Usefulness of early treatment with melatonin to reduce infarct size in patients with ST-elevation Myocardial infarction receiving percutaneous coronary intervention. Am J Cardiol., 120:522–526. doi: 10.1016/j.amjcard.2017.05.018.
Halpern B, Mancini MC, Bueno C, BarcelosIP, de MeloME, LimaMS, CarneiroCG, SapienzaMT, BuchpiguelCA, do AmaralFG, Cipolla-NetoJ. (2019). Melatonin increases brown adipose tissue volume and activity in patients with melatonin deficiency: a proof-of-concept study. Diabetes, 68:947–952. doi: 10.2337/db18-0956.
Jockers R, Delagrange P, Dubocovich ML, Markus RP, Renault N, Tosini G., Cecon E, ZlotosDP. (2016). Update on melatonin receptors: IUPHAR Review 20. Br J Pharmacol.,173:2702–25. doi: 10.1111/bph.13536.
Kandimalla R, Thirumala V, Reddy PH. (2017). Is Alzheimer's disease a Type 3 Diabetes? A critical appraisal. BiochimBiophysActaMol Basis Dis., 1863:1078– 89. doi: 10.1016/j.bbadis.2016.08.018.
Karamitri A, Renault N, Clement N, Guillaume JL, Jockers R. (2013). Minireview: Toward the Establishment of a Link between Melatonin and Glucose Homeostasis: Association of Melatonin MT2 Receptor Variants with Type 2 Diabetes. MolEndocrinol.,27:1217– 1233. doi: 10.1210/me.2013-1101.
Lin YC, Hsieh IC, Chen PC. (2015). Utilizing the metabolic syndrome component count in workers' health surveillance: An example of day-time vs. day-night rotating shift workers. Int J Occup Med Environ Health.,28:675–88. doi: 10.13075/ijomeh.1896.00335.
Logan RW, McClungCA. (2019). Rhythms of life: circadian disruption and brain disorders across the lifespan. Nature Reviews Neuroscience, 20(1):49–65. doi: 10.1038/s41583-018-0088-y.
Maras A, Schroder CM, Malow BA, Findling RL, Breddy J, Nir T, Shahmoon S, Zisapel N, Gringras P. (2018). Long-Term Efficacy and Safety of Pediatric Prolonged-Release Melatonin in Children with Autism Spectrum Disorder. J Child Adolesc Psychopharmacol., 28(10):699-710. doi: 10.1089/cap.2018.0020.
Molzof HE, Wirth MD, Burch JB, Shivappa N, Hebert JR, Johnson RL,Gamble KL. (2017).The impact of meal timing on cardiometabolic syndrome indicators in shift workers. Chronobiol Int., 34:337–48. doi: 10.1080/07420528.2016.
Morris CJ, YangJN, GarciaJI, MyersS, BozziI, WangW, BuxtonOM, SheaSA, Scheer FAJ. (2015). Endogenous circadian system and circadian misalignment impact glucose tolerance via separate mechanisms in humans. Proc. Natl Acad. Sci. USA., 112:E2225–E2234.doi: 10.1073/pnas.1418955112.
Nedogoda SV, Smirnova VO, Bary`kina IN, Salasyuk AS, XripaevaVYu, Palashkin RV, Popova EA. (2017).Effect of melatonin therapy on endothelial function, blood pressure and vascular stiffness in patients with metabolic syndrome and sleep disorders.Arterial hypertension, 23(2):150–159. doi:10.18705/1607-419X-2017-23-2-150-159. (In Russian).
Ozkalayci F, Kocabas U, Altun BU, Pandi-Perumal S, Altun A. (2021). Relationship Between Melatonin and Cardiovascular Disease. Cureus, 13(1):e12935. doi: 10.7759/cureus.12935.
Queiroz JDN, Macedo RCO, Tinsley GM, Reischak-Oliveira A. (2021). Time-restricted eating and circadian rhythms: The biological clock is ticking. Crit. Rev. Food Sci. Nutr., 61(17):2863–3875. doi: 10.1080/10408398.2020.1789550.
Pizova NV, Pizov AV, Solov`eva IN. (2022). Insomnia: risk factors, gender and age characteristics and approaches to treatment.Medical advice, 16(11):62-70. https://doi.org/10.21518/2079-701X-2022-16-11-62-70. (In Russian).
Popov SS,Pashkov AN, Shul`gin KK. (2015). The effect of combination therapy with melaxen on carbohydrate and lipid metabolism in patients with type 2 diabetes mellitus complicated by non-alcoholic steatohepatitis.Bulletin of Voronezh State University, 4:66-70. (In Russian).
Ramos AR,Weng J, WallaceDM, PetrovMR, WohlgemuthWK, Sotres-Alvarez D, Loredo JS, Reid KJ, ZeePC, Mossavar-RahmaniY, PateSR. (2018). Sleep patterns and hypertension using actigraphy in the Hispanic Community Health Study/Study of Latinos.Chest.,153:87– 93. doi: 10.1016/j.chest.2017.09.028.
Shen S, Liao Q, Wong YK, Chen X, Yang C, Xu C, Sun J, Wang J. (2022). The role of melatonin in the treatment of type 2 diabetes mellitus and Alzheimer’s disease. Int J Biol Sci., 18(3):983-994. doi: 10.7150/ijbs.66871.
Sobko DI, Ilashchuk TO, Navchuk IV. (2021). Melatonin and Grhelin as “Early” Prognosis Markers of Progression of Arterial Hypertension and Osteoarthritis in the Case of Their Comorbidity. WiadLek., 74(3 cz 2):697-701.
Stenvers DJ, ScheerFAJ, SchrauwenP, la FleurSE, KalsbeekA. (2019). Circadian clocks and insulin resistance. Nature Reviews Endocrinology, 15(2):75–89. doi: 10.1038/s41574-018-0122-1.
Sumsuzzman DM, Choi J, Jin Y, Hong Y. (2021). Neurocognitive effects of melatonin treatment in healthy adults and individuals with Alzheimer’s disease and insomnia: A systematic review and meta-analysis of randomized controlled trials. NeurosciBiobehav Rev., 127:459-473. doi: 10.1016/j.neubiorev.2021.04.034.0
Tobaldini E, Fiorelli EM, Solbiati M, Costantino G, Nobili L, Montano N. (2019). Short sleep duration and cardiometabolic risk: from pathophysiology to clinical evidence. Nat Rev Cardiol., 16:213–224. https://doi. org/10.1038/s41569-018-0109-6.
Vasendin DV, Michurina SV, IshhenkoIYu. (2023). The effect of melatonin on the ultrastructural organization of the liver in obesity and type 2 diabetes mellitus.Cardiovascular Therapy and Prevention,22(6S):110. (In Russian).
Vasendin DV, Michurina SV, IshhenkoIYu. (2023). The influence of a melatonin-containing composition on the state of lipid metabolism in the liver in obesity and type 2 diabetes mellitus.Cardiovascular Therapy and Prevention, 22(6S):110. (In Russian).
Wajid F, Poolacherla R, Mim FK, Bangash A, Rutkofsky IH. (2020). Therapeutic potential of melatonin as a chronobiotic and cytoprotective agent in diabetes mellitus. J Diabetes Metab Disord., 19(2):1797-1825. doi: 10.1007/s40200-020-00585-2.
Zhu H, Zhao ZJ, Liu HY, Cai J, Lu QK, Ji LD, Xu J. (2023). The melatonin receptor 1 B gene links circadian rhythms and type 2 diabetes mellitus: an evolutionary story. Ann Med., 55(1):1262-1286. doi: 10.1080/07853890.2023.2191218.
Publicado
2024-04-25
Cómo citar
Kurdiukova, D. S., Gasanbekov, G. M., Pavlov, B. V., Kulikova, I. A., Martynova, G. D., & Kislinskaya, N. A. (2024). El efecto de la melatonina sobre el metabolismo y el ciclo sueño-vigilia. Revista De La Universidad Del Zulia, 15(43), 130-147. https://doi.org/10.46925//rdluz.43.09
Número
Sección
Artículos
Copyright
La Revista de la Universidad del Zulia declara que reconoce los derechos de los autores de los trabajos originales que en ella se publican; dichos trabajos son propiedad intelectual de sus autores. Los autores preservan sus derechos de autoría y comparten sin propósitos comerciales, según la licencia adoptada por la revista..
Esta obra está bajo la licencia:
Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional (CC BY-NC-SA 4.0)
